Jubilant Life Sciences to produce COVID-19 drug; Nanjangud plant still closed
COVID-19, News

Jubilant Life Sciences to produce COVID-19 drug; Nanjangud plant still closed

May 13, 2020

Mysore/Mysuru: Jubilant Life Sciences Limited,  an India-based Pharmaceutical and Life Sciences Company, yesterday announced that its subsidiary, Jubilant Generics Limited, has entered into a non-exclusive licensing agreement with Gilead Sciences that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug ‘Remdesivir’, a potential therapy for COVID-19 in 127 countries including India.

“Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to COVID-19 patients upon approvals by regulatory authorities in respective countries,” a press statement on the Jubilant Company website said.

Nanjangud connection

Jubilant Generics Limited has a plant in Nanjangud, Mysuru District. It may be recalled that the plant hit headlines recently after one of its employees (now identified as P52) contracted the Coronavirus.

Though the Karnataka Department of Health and Family Welfare has identified the first patient from Jubilant Generics as a ‘super spreader’ of COVID-19 in the State, it still remains a mystery as to how P52, an employee of the Quality Assurance Department, contracted the disease. Later, the disease spread to 73 persons, forcing the Mysuru District Administration to declare Nanjangud as a cluster case.

Senior IAS Officer Harsha Gupta, who was appointed by the State Government to investigate the actual source of the virus, submitted an incomplete report. “When we do not exactly know how the disease came to India, what is the point in spending hours on the Nanjangud cluster? The aim should be on how to control the spread of disease and not conduct a probe on the actual source,” he had said.

Production shut

READ ALSO  Labourers screened at Hunsur border

Production at the Jubilant Generics was shut due to Coronavirus positive cases and the Mysuru District Administration quarantined the entire staff of around 950 persons in the plant and adjoining areas. The Nanjangud Plant manufactures Active Pharmaceutical Ingredients (APIs) which in simple terms mean raw material to manufacture drugs. 

It is not, however, clear if the production of APIs will start at the Nanjangud Plant as at present, the manufacturing unit is shut. Company officials at Noida were not available for comments and there were only security personnel at the Nanjangud Plant who had no information about production.

ONE COMMENT ON THIS POST To “Jubilant Life Sciences to produce COVID-19 drug; Nanjangud plant still closed”

  1. PSRao says:

    Yes. The point is to control the spread of virus rather than the identification of probe, so once the spreading is stopped manufacturing can be allowed by following Govt guidelines like other companies.


Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 45 years, Star of Mysore has been the newspaper that Mysureans reach for every evening to know about the happenings in Mysuru city. The newspaper has feature rich articles and dedicated pages targeted at readers across the demographic spectrum of Mysuru city. With a readership of over 2,50,000 Star of Mysore has been the best connection between it’s readers and their leaders; between advertisers and customers; between Mysuru and Mysureans.


Academy News Papers Private Limited, Publishers, Star of Mysore & Mysuru Mithra, 15-C, Industrial ‘A’ Layout, Bannimantap, Mysuru-570015. Phone no. – 0821 249 6520

To advertise on Star of Mysore, email us at

Online Edition: [email protected]
Print Editon: [email protected]
For News/Press Release: [email protected]